nodes	percent_of_prediction	percent_of_DWPC	metapath
Epinephrine—TNF—urinary bladder cancer	0.541	1	CbGaD
Epinephrine—SLC22A2—Cisplatin—urinary bladder cancer	0.0345	0.323	CbGbCtD
Epinephrine—ADRA1B—vas deferens—urinary bladder cancer	0.0264	0.264	CbGeAlD
Epinephrine—CYP3A4—Thiotepa—urinary bladder cancer	0.0199	0.187	CbGbCtD
Epinephrine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0123	0.116	CbGbCtD
Epinephrine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0111	0.104	CbGbCtD
Epinephrine—CYP1A2—Etoposide—urinary bladder cancer	0.0103	0.0966	CbGbCtD
Epinephrine—CYP2C9—Cisplatin—urinary bladder cancer	0.00945	0.0886	CbGbCtD
Epinephrine—CYP3A4—Etoposide—urinary bladder cancer	0.0054	0.0506	CbGbCtD
Epinephrine—ADRB3—prostate gland—urinary bladder cancer	0.0041	0.041	CbGeAlD
Epinephrine—ADRBK1—prostate gland—urinary bladder cancer	0.00401	0.0401	CbGeAlD
Epinephrine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00368	0.0345	CbGbCtD
Epinephrine—PAH—renal system—urinary bladder cancer	0.00358	0.0358	CbGeAlD
Epinephrine—TNF—vagina—urinary bladder cancer	0.00345	0.0345	CbGeAlD
Epinephrine—CYP1A2—urine—urinary bladder cancer	0.00305	0.0306	CbGeAlD
Epinephrine—CYP2C9—urine—urinary bladder cancer	0.0029	0.029	CbGeAlD
Epinephrine—ADRBK1—smooth muscle tissue—urinary bladder cancer	0.00284	0.0284	CbGeAlD
Epinephrine—ADRBK1—renal system—urinary bladder cancer	0.00273	0.0273	CbGeAlD
Epinephrine—ADRA1D—prostate gland—urinary bladder cancer	0.00231	0.0231	CbGeAlD
Epinephrine—ADRB3—female reproductive system—urinary bladder cancer	0.00224	0.0224	CbGeAlD
Epinephrine—TNF—lymph node—urinary bladder cancer	0.00223	0.0223	CbGeAlD
Epinephrine—CYP3A4—urine—urinary bladder cancer	0.00221	0.0221	CbGeAlD
Epinephrine—ADRBK1—female reproductive system—urinary bladder cancer	0.00219	0.0219	CbGeAlD
Epinephrine—ADRBK1—vagina—urinary bladder cancer	0.00198	0.0198	CbGeAlD
Epinephrine—Cerebral haemorrhage—Thiotepa—urinary bladder cancer	0.00195	0.0143	CcSEcCtD
Epinephrine—Pulmonary oedema—Mitomycin—urinary bladder cancer	0.00191	0.014	CcSEcCtD
Epinephrine—Lactic acidosis—Epirubicin—urinary bladder cancer	0.00178	0.013	CcSEcCtD
Epinephrine—Hyperglycaemia—Valrubicin—urinary bladder cancer	0.00176	0.0129	CcSEcCtD
Epinephrine—ADRA1D—epithelium—urinary bladder cancer	0.0017	0.017	CbGeAlD
Epinephrine—SLC22A2—renal system—urinary bladder cancer	0.00168	0.0168	CbGeAlD
Epinephrine—ADRB1—prostate gland—urinary bladder cancer	0.00168	0.0168	CbGeAlD
Epinephrine—Lactic acidosis—Doxorubicin—urinary bladder cancer	0.00165	0.0121	CcSEcCtD
Epinephrine—Renal impairment—Mitomycin—urinary bladder cancer	0.00164	0.012	CcSEcCtD
Epinephrine—Nephropathy—Etoposide—urinary bladder cancer	0.00163	0.0119	CcSEcCtD
Epinephrine—Local reaction—Fluorouracil—urinary bladder cancer	0.00161	0.0118	CcSEcCtD
Epinephrine—ADRA1B—renal system—urinary bladder cancer	0.00161	0.0161	CbGeAlD
Epinephrine—ADRA1D—urethra—urinary bladder cancer	0.00155	0.0155	CbGeAlD
Epinephrine—Memory impairment—Thiotepa—urinary bladder cancer	0.00138	0.0101	CcSEcCtD
Epinephrine—Skin necrosis—Methotrexate—urinary bladder cancer	0.00133	0.00972	CcSEcCtD
Epinephrine—ADRA1A—prostate gland—urinary bladder cancer	0.00133	0.0133	CbGeAlD
Epinephrine—ADRBK1—lymph node—urinary bladder cancer	0.00128	0.0128	CbGeAlD
Epinephrine—ADRA2C—prostate gland—urinary bladder cancer	0.00126	0.0126	CbGeAlD
Epinephrine—ADRA1D—female reproductive system—urinary bladder cancer	0.00126	0.0126	CbGeAlD
Epinephrine—Skin necrosis—Epirubicin—urinary bladder cancer	0.00124	0.0091	CcSEcCtD
Epinephrine—Extravasation—Thiotepa—urinary bladder cancer	0.00124	0.00905	CcSEcCtD
Epinephrine—Hemiplegia—Epirubicin—urinary bladder cancer	0.00122	0.0089	CcSEcCtD
Epinephrine—SLC22A5—prostate gland—urinary bladder cancer	0.00121	0.0121	CbGeAlD
Epinephrine—Drowsiness—Mitomycin—urinary bladder cancer	0.0012	0.00878	CcSEcCtD
Epinephrine—SLC22A1—renal system—urinary bladder cancer	0.00119	0.0119	CbGeAlD
Epinephrine—Renal failure—Mitomycin—urinary bladder cancer	0.00118	0.00864	CcSEcCtD
Epinephrine—Chest pain—Valrubicin—urinary bladder cancer	0.00116	0.00848	CcSEcCtD
Epinephrine—Skin necrosis—Doxorubicin—urinary bladder cancer	0.00115	0.00842	CcSEcCtD
Epinephrine—Necrosis—Fluorouracil—urinary bladder cancer	0.00114	0.00832	CcSEcCtD
Epinephrine—Rales—Methotrexate—urinary bladder cancer	0.00113	0.00828	CcSEcCtD
Epinephrine—Hemiplegia—Doxorubicin—urinary bladder cancer	0.00113	0.00824	CcSEcCtD
Epinephrine—Tingling sensation—Fluorouracil—urinary bladder cancer	0.00111	0.00813	CcSEcCtD
Epinephrine—Myocardial ischaemia—Fluorouracil—urinary bladder cancer	0.00111	0.00813	CcSEcCtD
Epinephrine—Necrosis—Cisplatin—urinary bladder cancer	0.00108	0.00789	CcSEcCtD
Epinephrine—ADRA2C—seminal vesicle—urinary bladder cancer	0.00107	0.0107	CbGeAlD
Epinephrine—Extravasation—Gemcitabine—urinary bladder cancer	0.00104	0.00761	CcSEcCtD
Epinephrine—Skin exfoliation—Thiotepa—urinary bladder cancer	0.00103	0.00754	CcSEcCtD
Epinephrine—Extravasation—Fluorouracil—urinary bladder cancer	0.00102	0.00749	CcSEcCtD
Epinephrine—SLC22A5—seminal vesicle—urinary bladder cancer	0.00102	0.0102	CbGeAlD
Epinephrine—ADRA2A—prostate gland—urinary bladder cancer	0.00101	0.0101	CbGeAlD
Epinephrine—Necrosis—Etoposide—urinary bladder cancer	0.000988	0.00723	CcSEcCtD
Epinephrine—Drug interaction—Gemcitabine—urinary bladder cancer	0.000979	0.00716	CcSEcCtD
Epinephrine—Nephropathy—Methotrexate—urinary bladder cancer	0.000976	0.00714	CcSEcCtD
Epinephrine—ADRA1A—epithelium—urinary bladder cancer	0.000974	0.00975	CbGeAlD
Epinephrine—Extravasation—Cisplatin—urinary bladder cancer	0.00097	0.0071	CcSEcCtD
Epinephrine—Tingling sensation—Etoposide—urinary bladder cancer	0.000965	0.00706	CcSEcCtD
Epinephrine—Pulmonary oedema—Thiotepa—urinary bladder cancer	0.000961	0.00703	CcSEcCtD
Epinephrine—Erythema—Mitomycin—urinary bladder cancer	0.000939	0.00686	CcSEcCtD
Epinephrine—ADRB1—female reproductive system—urinary bladder cancer	0.000915	0.00916	CbGeAlD
Epinephrine—ADRA1A—renal system—urinary bladder cancer	0.000904	0.00904	CbGeAlD
Epinephrine—Extravasation—Etoposide—urinary bladder cancer	0.000889	0.0065	CcSEcCtD
Epinephrine—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.000867	0.00634	CcSEcCtD
Epinephrine—ADRA2C—renal system—urinary bladder cancer	0.000861	0.00862	CbGeAlD
Epinephrine—SLC22A1—vagina—urinary bladder cancer	0.00086	0.0086	CbGeAlD
Epinephrine—ADRA2A—seminal vesicle—urinary bladder cancer	0.000853	0.00853	CbGeAlD
Epinephrine—ADRA2C—urethra—urinary bladder cancer	0.000846	0.00847	CbGeAlD
Epinephrine—SLC22A5—renal system—urinary bladder cancer	0.000825	0.00825	CbGeAlD
Epinephrine—Hypertension—Mitomycin—urinary bladder cancer	0.00081	0.00593	CcSEcCtD
Epinephrine—SLC22A5—urethra—urinary bladder cancer	0.00081	0.00811	CbGeAlD
Epinephrine—Pulmonary oedema—Gemcitabine—urinary bladder cancer	0.000809	0.00591	CcSEcCtD
Epinephrine—Skin exfoliation—Cisplatin—urinary bladder cancer	0.000808	0.00591	CcSEcCtD
Epinephrine—Local reaction—Epirubicin—urinary bladder cancer	0.000785	0.00574	CcSEcCtD
Epinephrine—CYP1A2—renal system—urinary bladder cancer	0.000747	0.00748	CbGeAlD
Epinephrine—Skin exfoliation—Etoposide—urinary bladder cancer	0.000741	0.00542	CcSEcCtD
Epinephrine—Dizziness—Valrubicin—urinary bladder cancer	0.000735	0.00538	CcSEcCtD
Epinephrine—Local reaction—Doxorubicin—urinary bladder cancer	0.000727	0.00531	CcSEcCtD
Epinephrine—Disorientation—Fluorouracil—urinary bladder cancer	0.000725	0.0053	CcSEcCtD
Epinephrine—Vomiting—Valrubicin—urinary bladder cancer	0.000707	0.00517	CcSEcCtD
Epinephrine—Renal impairment—Gemcitabine—urinary bladder cancer	0.000693	0.00507	CcSEcCtD
Epinephrine—Somnolence—Mitomycin—urinary bladder cancer	0.000681	0.00498	CcSEcCtD
Epinephrine—ADRA2A—urethra—urinary bladder cancer	0.000675	0.00675	CbGeAlD
Epinephrine—Cerebrovascular accident—Gemcitabine—urinary bladder cancer	0.000673	0.00492	CcSEcCtD
Epinephrine—SLC22A5—female reproductive system—urinary bladder cancer	0.000661	0.00661	CbGeAlD
Epinephrine—Nausea—Valrubicin—urinary bladder cancer	0.000661	0.00483	CcSEcCtD
Epinephrine—Cerebrovascular accident—Cisplatin—urinary bladder cancer	0.000627	0.00459	CcSEcCtD
Epinephrine—ADRA2C—vagina—urinary bladder cancer	0.000624	0.00624	CbGeAlD
Epinephrine—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.000611	0.00447	CcSEcCtD
Epinephrine—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.0006	0.00439	CcSEcCtD
Epinephrine—SLC22A5—vagina—urinary bladder cancer	0.000597	0.00598	CbGeAlD
Epinephrine—Renal failure—Thiotepa—urinary bladder cancer	0.000594	0.00434	CcSEcCtD
Epinephrine—Necrosis—Methotrexate—urinary bladder cancer	0.000592	0.00433	CcSEcCtD
Epinephrine—Ventricular arrhythmia—Epirubicin—urinary bladder cancer	0.000587	0.0043	CcSEcCtD
Epinephrine—CYP2C9—female reproductive system—urinary bladder cancer	0.000568	0.00568	CbGeAlD
Epinephrine—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000559	0.00409	CcSEcCtD
Epinephrine—Necrosis—Epirubicin—urinary bladder cancer	0.000554	0.00405	CcSEcCtD
Epinephrine—ADRA2A—female reproductive system—urinary bladder cancer	0.00055	0.00551	CbGeAlD
Epinephrine—Haemoglobin—Thiotepa—urinary bladder cancer	0.000545	0.00399	CcSEcCtD
Epinephrine—Ventricular arrhythmia—Doxorubicin—urinary bladder cancer	0.000544	0.00398	CcSEcCtD
Epinephrine—Haemorrhage—Thiotepa—urinary bladder cancer	0.000542	0.00397	CcSEcCtD
Epinephrine—CYP3A4—renal system—urinary bladder cancer	0.000541	0.00541	CbGeAlD
Epinephrine—Hallucination—Thiotepa—urinary bladder cancer	0.00054	0.00395	CcSEcCtD
Epinephrine—Extravasation—Methotrexate—urinary bladder cancer	0.000533	0.00389	CcSEcCtD
Epinephrine—Sweating increased—Cisplatin—urinary bladder cancer	0.000517	0.00378	CcSEcCtD
Epinephrine—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.000514	0.00376	CcSEcCtD
Epinephrine—Necrosis—Doxorubicin—urinary bladder cancer	0.000513	0.00375	CcSEcCtD
Epinephrine—Dizziness—Mitomycin—urinary bladder cancer	0.000507	0.0037	CcSEcCtD
Epinephrine—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.000501	0.00366	CcSEcCtD
Epinephrine—Renal failure—Gemcitabine—urinary bladder cancer	0.0005	0.00365	CcSEcCtD
Epinephrine—Extravasation—Epirubicin—urinary bladder cancer	0.000498	0.00364	CcSEcCtD
Epinephrine—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.000498	0.00364	CcSEcCtD
Epinephrine—ADRA2A—vagina—urinary bladder cancer	0.000498	0.00498	CbGeAlD
Epinephrine—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.000493	0.0036	CcSEcCtD
Epinephrine—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.00049	0.00358	CcSEcCtD
Epinephrine—Sweating—Gemcitabine—urinary bladder cancer	0.000487	0.00356	CcSEcCtD
Epinephrine—Vomiting—Mitomycin—urinary bladder cancer	0.000487	0.00356	CcSEcCtD
Epinephrine—Arrhythmia—Thiotepa—urinary bladder cancer	0.000484	0.00354	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Epirubicin—urinary bladder cancer	0.000481	0.00352	CcSEcCtD
Epinephrine—Mental disorder—Thiotepa—urinary bladder cancer	0.000475	0.00347	CcSEcCtD
Epinephrine—Sweating increased—Etoposide—urinary bladder cancer	0.000474	0.00347	CcSEcCtD
Epinephrine—Erythema—Thiotepa—urinary bladder cancer	0.000472	0.00345	CcSEcCtD
Epinephrine—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000467	0.00341	CcSEcCtD
Epinephrine—Renal failure—Cisplatin—urinary bladder cancer	0.000466	0.0034	CcSEcCtD
Epinephrine—Myocardial infarction—Cisplatin—urinary bladder cancer	0.000464	0.0034	CcSEcCtD
Epinephrine—Tension—Thiotepa—urinary bladder cancer	0.000463	0.00339	CcSEcCtD
Epinephrine—Extravasation—Doxorubicin—urinary bladder cancer	0.000461	0.00337	CcSEcCtD
Epinephrine—Nervousness—Thiotepa—urinary bladder cancer	0.000459	0.00335	CcSEcCtD
Epinephrine—Haemoglobin—Gemcitabine—urinary bladder cancer	0.000459	0.00335	CcSEcCtD
Epinephrine—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000456	0.00334	CcSEcCtD
Epinephrine—Nausea—Mitomycin—urinary bladder cancer	0.000455	0.00333	CcSEcCtD
Epinephrine—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000451	0.0033	CcSEcCtD
Epinephrine—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000449	0.00328	CcSEcCtD
Epinephrine—Hypoaesthesia—Fluorouracil—urinary bladder cancer	0.000446	0.00326	CcSEcCtD
Epinephrine—Ventricular extrasystoles—Doxorubicin—urinary bladder cancer	0.000445	0.00326	CcSEcCtD
Epinephrine—Skin exfoliation—Methotrexate—urinary bladder cancer	0.000444	0.00324	CcSEcCtD
Epinephrine—Agitation—Thiotepa—urinary bladder cancer	0.000434	0.00317	CcSEcCtD
Epinephrine—CYP3A4—female reproductive system—urinary bladder cancer	0.000433	0.00433	CbGeAlD
Epinephrine—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000428	0.00313	CcSEcCtD
Epinephrine—Renal failure—Etoposide—urinary bladder cancer	0.000427	0.00312	CcSEcCtD
Epinephrine—Myocardial infarction—Etoposide—urinary bladder cancer	0.000425	0.00311	CcSEcCtD
Epinephrine—Skin exfoliation—Epirubicin—urinary bladder cancer	0.000415	0.00304	CcSEcCtD
Epinephrine—Pulmonary oedema—Methotrexate—urinary bladder cancer	0.000414	0.00302	CcSEcCtD
Epinephrine—Hypertension—Thiotepa—urinary bladder cancer	0.000408	0.00298	CcSEcCtD
Epinephrine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000408	0.00298	CcSEcCtD
Epinephrine—ADRA2C—lymph node—urinary bladder cancer	0.000403	0.00404	CbGeAlD
Epinephrine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000401	0.00293	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000399	0.00292	CcSEcCtD
Epinephrine—Erythema—Gemcitabine—urinary bladder cancer	0.000397	0.0029	CcSEcCtD
Epinephrine—Flushing—Cisplatin—urinary bladder cancer	0.000395	0.00289	CcSEcCtD
Epinephrine—Erythema—Fluorouracil—urinary bladder cancer	0.00039	0.00286	CcSEcCtD
Epinephrine—Hypoaesthesia—Etoposide—urinary bladder cancer	0.000388	0.00283	CcSEcCtD
Epinephrine—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.000387	0.00283	CcSEcCtD
Epinephrine—SLC22A5—lymph node—urinary bladder cancer	0.000386	0.00387	CbGeAlD
Epinephrine—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.000384	0.00281	CcSEcCtD
Epinephrine—Arrhythmia—Cisplatin—urinary bladder cancer	0.00038	0.00278	CcSEcCtD
Epinephrine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000378	0.00276	CcSEcCtD
Epinephrine—Tachycardia—Thiotepa—urinary bladder cancer	0.000376	0.00275	CcSEcCtD
Epinephrine—Skin disorder—Thiotepa—urinary bladder cancer	0.000374	0.00274	CcSEcCtD
Epinephrine—Erythema—Cisplatin—urinary bladder cancer	0.00037	0.00271	CcSEcCtD
Epinephrine—Flushing—Etoposide—urinary bladder cancer	0.000362	0.00264	CcSEcCtD
Epinephrine—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.000358	0.00262	CcSEcCtD
Epinephrine—Paraesthesia—Thiotepa—urinary bladder cancer	0.000346	0.00253	CcSEcCtD
Epinephrine—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000344	0.00252	CcSEcCtD
Epinephrine—Hypertension—Gemcitabine—urinary bladder cancer	0.000343	0.00251	CcSEcCtD
Epinephrine—Somnolence—Thiotepa—urinary bladder cancer	0.000343	0.0025	CcSEcCtD
Epinephrine—Chest pain—Gemcitabine—urinary bladder cancer	0.000338	0.00247	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000336	0.00246	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000333	0.00243	CcSEcCtD
Epinephrine—Chest pain—Fluorouracil—urinary bladder cancer	0.000332	0.00243	CcSEcCtD
Epinephrine—Renal impairment—Epirubicin—urinary bladder cancer	0.000332	0.00243	CcSEcCtD
Epinephrine—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000323	0.00237	CcSEcCtD
Epinephrine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000322	0.00236	CcSEcCtD
Epinephrine—ADRA2A—lymph node—urinary bladder cancer	0.000322	0.00322	CbGeAlD
Epinephrine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000318	0.00232	CcSEcCtD
Epinephrine—Skin disorder—Gemcitabine—urinary bladder cancer	0.000315	0.0023	CcSEcCtD
Epinephrine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000313	0.00229	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000313	0.00229	CcSEcCtD
Epinephrine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000313	0.00229	CcSEcCtD
Epinephrine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000311	0.00227	CcSEcCtD
Epinephrine—Renal impairment—Doxorubicin—urinary bladder cancer	0.000307	0.00224	CcSEcCtD
Epinephrine—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000299	0.00219	CcSEcCtD
Epinephrine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000298	0.00218	CcSEcCtD
Epinephrine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000296	0.00217	CcSEcCtD
Epinephrine—Tachycardia—Cisplatin—urinary bladder cancer	0.000295	0.00216	CcSEcCtD
Epinephrine—Skin disorder—Cisplatin—urinary bladder cancer	0.000293	0.00215	CcSEcCtD
Epinephrine—Insomnia—Gemcitabine—urinary bladder cancer	0.000293	0.00214	CcSEcCtD
Epinephrine—Hypertension—Etoposide—urinary bladder cancer	0.000293	0.00214	CcSEcCtD
Epinephrine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000292	0.00214	CcSEcCtD
Epinephrine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000291	0.00213	CcSEcCtD
Epinephrine—Chest pain—Etoposide—urinary bladder cancer	0.000289	0.00211	CcSEcCtD
Epinephrine—Insomnia—Fluorouracil—urinary bladder cancer	0.000288	0.00211	CcSEcCtD
Epinephrine—Somnolence—Gemcitabine—urinary bladder cancer	0.000288	0.00211	CcSEcCtD
Epinephrine—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000287	0.0021	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000287	0.0021	CcSEcCtD
Epinephrine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000286	0.00209	CcSEcCtD
Epinephrine—Somnolence—Fluorouracil—urinary bladder cancer	0.000283	0.00207	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00028	0.00205	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000275	0.00201	CcSEcCtD
Epinephrine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000271	0.00198	CcSEcCtD
Epinephrine—Tachycardia—Etoposide—urinary bladder cancer	0.00027	0.00198	CcSEcCtD
Epinephrine—Skin disorder—Etoposide—urinary bladder cancer	0.000269	0.00197	CcSEcCtD
Epinephrine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000268	0.00196	CcSEcCtD
Epinephrine—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000266	0.00194	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000261	0.00191	CcSEcCtD
Epinephrine—Drowsiness—Methotrexate—urinary bladder cancer	0.00026	0.0019	CcSEcCtD
Epinephrine—Renal failure—Methotrexate—urinary bladder cancer	0.000256	0.00187	CcSEcCtD
Epinephrine—Dizziness—Thiotepa—urinary bladder cancer	0.000255	0.00186	CcSEcCtD
Epinephrine—Sweating—Methotrexate—urinary bladder cancer	0.000249	0.00182	CcSEcCtD
Epinephrine—Paraesthesia—Etoposide—urinary bladder cancer	0.000249	0.00182	CcSEcCtD
Epinephrine—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000246	0.0018	CcSEcCtD
Epinephrine—Somnolence—Etoposide—urinary bladder cancer	0.000246	0.0018	CcSEcCtD
Epinephrine—Vomiting—Thiotepa—urinary bladder cancer	0.000245	0.00179	CcSEcCtD
Epinephrine—Drowsiness—Epirubicin—urinary bladder cancer	0.000243	0.00178	CcSEcCtD
Epinephrine—Renal failure—Epirubicin—urinary bladder cancer	0.000239	0.00175	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000239	0.00175	CcSEcCtD
Epinephrine—Haemoglobin—Methotrexate—urinary bladder cancer	0.000235	0.00172	CcSEcCtD
Epinephrine—Haemorrhage—Methotrexate—urinary bladder cancer	0.000233	0.00171	CcSEcCtD
Epinephrine—Sweating—Epirubicin—urinary bladder cancer	0.000233	0.00171	CcSEcCtD
Epinephrine—Nausea—Thiotepa—urinary bladder cancer	0.000229	0.00167	CcSEcCtD
Epinephrine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000228	0.00167	CcSEcCtD
Epinephrine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000225	0.00165	CcSEcCtD
Epinephrine—Renal failure—Doxorubicin—urinary bladder cancer	0.000221	0.00162	CcSEcCtD
Epinephrine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000219	0.0016	CcSEcCtD
Epinephrine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000218	0.0016	CcSEcCtD
Epinephrine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000217	0.00159	CcSEcCtD
Epinephrine—Sweating—Doxorubicin—urinary bladder cancer	0.000216	0.00158	CcSEcCtD
Epinephrine—Dizziness—Fluorouracil—urinary bladder cancer	0.000211	0.00154	CcSEcCtD
Epinephrine—Vomiting—Gemcitabine—urinary bladder cancer	0.000206	0.00151	CcSEcCtD
Epinephrine—Mental disorder—Methotrexate—urinary bladder cancer	0.000204	0.00149	CcSEcCtD
Epinephrine—Erythema—Methotrexate—urinary bladder cancer	0.000203	0.00149	CcSEcCtD
Epinephrine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000203	0.00149	CcSEcCtD
Epinephrine—Flushing—Epirubicin—urinary bladder cancer	0.000203	0.00148	CcSEcCtD
Epinephrine—Vomiting—Fluorouracil—urinary bladder cancer	0.000203	0.00148	CcSEcCtD
Epinephrine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000202	0.00148	CcSEcCtD
Epinephrine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000201	0.00147	CcSEcCtD
Epinephrine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000195	0.00143	CcSEcCtD
Epinephrine—Nausea—Gemcitabine—urinary bladder cancer	0.000193	0.00141	CcSEcCtD
Epinephrine—Vomiting—Cisplatin—urinary bladder cancer	0.000192	0.0014	CcSEcCtD
Epinephrine—Mental disorder—Epirubicin—urinary bladder cancer	0.000191	0.0014	CcSEcCtD
Epinephrine—Erythema—Epirubicin—urinary bladder cancer	0.00019	0.00139	CcSEcCtD
Epinephrine—Nausea—Fluorouracil—urinary bladder cancer	0.000189	0.00138	CcSEcCtD
Epinephrine—Flushing—Doxorubicin—urinary bladder cancer	0.000188	0.00137	CcSEcCtD
Epinephrine—Tension—Epirubicin—urinary bladder cancer	0.000187	0.00136	CcSEcCtD
Epinephrine—Nervousness—Epirubicin—urinary bladder cancer	0.000185	0.00135	CcSEcCtD
Epinephrine—Dizziness—Etoposide—urinary bladder cancer	0.000183	0.00134	CcSEcCtD
Epinephrine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.00018	0.00132	CcSEcCtD
Epinephrine—Nausea—Cisplatin—urinary bladder cancer	0.000179	0.00131	CcSEcCtD
Epinephrine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000177	0.00129	CcSEcCtD
Epinephrine—Vomiting—Etoposide—urinary bladder cancer	0.000176	0.00129	CcSEcCtD
Epinephrine—Erythema—Doxorubicin—urinary bladder cancer	0.000176	0.00129	CcSEcCtD
Epinephrine—Agitation—Epirubicin—urinary bladder cancer	0.000175	0.00128	CcSEcCtD
Epinephrine—Chest pain—Methotrexate—urinary bladder cancer	0.000173	0.00126	CcSEcCtD
Epinephrine—Tension—Doxorubicin—urinary bladder cancer	0.000173	0.00126	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000172	0.00126	CcSEcCtD
Epinephrine—Nervousness—Doxorubicin—urinary bladder cancer	0.000171	0.00125	CcSEcCtD
Epinephrine—Palpitations—Epirubicin—urinary bladder cancer	0.000168	0.00123	CcSEcCtD
Epinephrine—Nausea—Etoposide—urinary bladder cancer	0.000164	0.0012	CcSEcCtD
Epinephrine—Hypertension—Epirubicin—urinary bladder cancer	0.000164	0.0012	CcSEcCtD
Epinephrine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000163	0.00119	CcSEcCtD
Epinephrine—Chest pain—Epirubicin—urinary bladder cancer	0.000162	0.00118	CcSEcCtD
Epinephrine—Agitation—Doxorubicin—urinary bladder cancer	0.000162	0.00118	CcSEcCtD
Epinephrine—Skin disorder—Methotrexate—urinary bladder cancer	0.000161	0.00118	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000161	0.00118	CcSEcCtD
Epinephrine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00016	0.00117	CcSEcCtD
Epinephrine—Palpitations—Doxorubicin—urinary bladder cancer	0.000155	0.00114	CcSEcCtD
Epinephrine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000152	0.00111	CcSEcCtD
Epinephrine—Hypertension—Doxorubicin—urinary bladder cancer	0.000152	0.00111	CcSEcCtD
Epinephrine—Tachycardia—Epirubicin—urinary bladder cancer	0.000151	0.00111	CcSEcCtD
Epinephrine—Skin disorder—Epirubicin—urinary bladder cancer	0.000151	0.0011	CcSEcCtD
Epinephrine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00015	0.0011	CcSEcCtD
Epinephrine—Insomnia—Methotrexate—urinary bladder cancer	0.00015	0.0011	CcSEcCtD
Epinephrine—Chest pain—Doxorubicin—urinary bladder cancer	0.00015	0.0011	CcSEcCtD
Epinephrine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000149	0.00109	CcSEcCtD
Epinephrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000149	0.00109	CcSEcCtD
Epinephrine—Somnolence—Methotrexate—urinary bladder cancer	0.000147	0.00108	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000143	0.00105	CcSEcCtD
Epinephrine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000141	0.00103	CcSEcCtD
Epinephrine—Insomnia—Epirubicin—urinary bladder cancer	0.00014	0.00103	CcSEcCtD
Epinephrine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00014	0.00102	CcSEcCtD
Epinephrine—Skin disorder—Doxorubicin—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Epinephrine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000139	0.00102	CcSEcCtD
Epinephrine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000139	0.00101	CcSEcCtD
Epinephrine—Somnolence—Epirubicin—urinary bladder cancer	0.000138	0.00101	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000134	0.000979	CcSEcCtD
Epinephrine—Insomnia—Doxorubicin—urinary bladder cancer	0.00013	0.000949	CcSEcCtD
Epinephrine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000129	0.000943	CcSEcCtD
Epinephrine—Somnolence—Doxorubicin—urinary bladder cancer	0.000128	0.000933	CcSEcCtD
Epinephrine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000124	0.000906	CcSEcCtD
Epinephrine—Dizziness—Methotrexate—urinary bladder cancer	0.00011	0.000802	CcSEcCtD
Epinephrine—Vomiting—Methotrexate—urinary bladder cancer	0.000105	0.000771	CcSEcCtD
Epinephrine—Dizziness—Epirubicin—urinary bladder cancer	0.000103	0.00075	CcSEcCtD
Epinephrine—Vomiting—Epirubicin—urinary bladder cancer	9.86e-05	0.000721	CcSEcCtD
Epinephrine—Nausea—Methotrexate—urinary bladder cancer	9.85e-05	0.00072	CcSEcCtD
Epinephrine—Dizziness—Doxorubicin—urinary bladder cancer	9.49e-05	0.000694	CcSEcCtD
Epinephrine—Nausea—Epirubicin—urinary bladder cancer	9.21e-05	0.000674	CcSEcCtD
Epinephrine—Vomiting—Doxorubicin—urinary bladder cancer	9.13e-05	0.000667	CcSEcCtD
Epinephrine—Nausea—Doxorubicin—urinary bladder cancer	8.53e-05	0.000624	CcSEcCtD
Epinephrine—SLC22A1—Metabolism—PPARG—urinary bladder cancer	1.01e-05	8.75e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.01e-05	8.72e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CREBBP—urinary bladder cancer	1.01e-05	8.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	1e-05	8.65e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	9.97e-06	8.62e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—FGFR3—urinary bladder cancer	9.96e-06	8.62e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IGF1—urinary bladder cancer	9.93e-06	8.59e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—TP53—urinary bladder cancer	9.9e-06	8.57e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—EGFR—urinary bladder cancer	9.88e-06	8.55e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	9.81e-06	8.48e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.79e-06	8.46e-05	CbGpPWpGaD
Epinephrine—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	9.75e-06	8.43e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	9.72e-06	8.41e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—ESR1—urinary bladder cancer	9.68e-06	8.37e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	9.53e-06	8.24e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	9.52e-06	8.24e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	9.49e-06	8.21e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	9.47e-06	8.19e-05	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—TP53—urinary bladder cancer	9.37e-06	8.11e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—KRAS—urinary bladder cancer	9.34e-06	8.07e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	9.26e-06	8.01e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CREBBP—urinary bladder cancer	9.16e-06	7.93e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—MYC—urinary bladder cancer	9.16e-06	7.93e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—RHOA—urinary bladder cancer	9.1e-06	7.87e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CREBBP—urinary bladder cancer	9.08e-06	7.85e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IGF1—urinary bladder cancer	9.05e-06	7.83e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—EGFR—urinary bladder cancer	9.01e-06	7.79e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IGF1—urinary bladder cancer	8.97e-06	7.76e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CREBBP—urinary bladder cancer	8.96e-06	7.75e-05	CbGpPWpGaD
Epinephrine—ADRBK1—Signaling Pathways—HRAS—urinary bladder cancer	8.96e-06	7.75e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—EGFR—urinary bladder cancer	8.96e-06	7.75e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—EGFR—urinary bladder cancer	8.92e-06	7.72e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	8.91e-06	7.71e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IGF1—urinary bladder cancer	8.85e-06	7.66e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	8.85e-06	7.66e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	8.82e-06	7.63e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—EGFR—urinary bladder cancer	8.81e-06	7.62e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	8.71e-06	7.53e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	8.62e-06	7.45e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PPARG—urinary bladder cancer	8.58e-06	7.42e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	8.54e-06	7.39e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.54e-06	7.38e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—KRAS—urinary bladder cancer	8.51e-06	7.36e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CREBBP—urinary bladder cancer	8.48e-06	7.34e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—KRAS—urinary bladder cancer	8.47e-06	7.32e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	8.46e-06	7.32e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	8.43e-06	7.29e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—ERBB2—urinary bladder cancer	8.42e-06	7.28e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	8.41e-06	7.28e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IGF1—urinary bladder cancer	8.38e-06	7.24e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.36e-06	7.23e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	8.35e-06	7.22e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—EGFR—urinary bladder cancer	8.33e-06	7.21e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—KRAS—urinary bladder cancer	8.32e-06	7.2e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PTGS2—urinary bladder cancer	8.31e-06	7.18e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—RHOA—urinary bladder cancer	8.29e-06	7.17e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.25e-06	7.14e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.25e-06	7.14e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	8.24e-06	7.13e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	8.24e-06	7.13e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	8.21e-06	7.1e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	8.2e-06	7.09e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.14e-06	7.04e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—RHOA—urinary bladder cancer	8.11e-06	7.01e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	8.09e-06	7e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8e-06	6.92e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CXCL8—urinary bladder cancer	7.99e-06	6.91e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	7.96e-06	6.88e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling by GPCR—HRAS—urinary bladder cancer	7.94e-06	6.86e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	7.87e-06	6.81e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	7.86e-06	6.8e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	7.82e-06	6.76e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	7.75e-06	6.7e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	7.73e-06	6.69e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	7.73e-06	6.69e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—ERBB2—urinary bladder cancer	7.67e-06	6.64e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	7.67e-06	6.64e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	7.63e-06	6.6e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	7.6e-06	6.58e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	7.55e-06	6.53e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—TP53—urinary bladder cancer	7.53e-06	6.51e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—ERBB2—urinary bladder cancer	7.51e-06	6.49e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—PTEN—urinary bladder cancer	7.45e-06	6.44e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	7.44e-06	6.44e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	7.42e-06	6.41e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	7.4e-06	6.4e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	7.32e-06	6.33e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.29e-06	6.31e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	7.29e-06	6.3e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CXCL8—urinary bladder cancer	7.28e-06	6.29e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	7.27e-06	6.29e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—PTEN—urinary bladder cancer	7.24e-06	6.27e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling by GPCR—HRAS—urinary bladder cancer	7.23e-06	6.25e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	7.23e-06	6.25e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	7.21e-06	6.24e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	7.2e-06	6.23e-05	CbGpPWpGaD
Epinephrine—ADRB3—Signaling Pathways—HRAS—urinary bladder cancer	7.2e-06	6.22e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	7.19e-06	6.22e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	7.18e-06	6.21e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	7.16e-06	6.2e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	7.12e-06	6.16e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	7.1e-06	6.14e-05	CbGpPWpGaD
Epinephrine—SLC22A2—Metabolism—EP300—urinary bladder cancer	7.1e-06	6.14e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	7.07e-06	6.12e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	6.99e-06	6.05e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.96e-06	6.02e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	6.96e-06	6.02e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—PTEN—urinary bladder cancer	6.94e-06	6e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Metabolism—EP300—urinary bladder cancer	6.91e-06	5.98e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	6.89e-06	5.96e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	6.89e-06	5.96e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	6.88e-06	5.95e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	6.85e-06	5.92e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	6.83e-06	5.91e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	6.8e-06	5.88e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	6.8e-06	5.88e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	6.78e-06	5.86e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	6.77e-06	5.86e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	6.75e-06	5.84e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	6.74e-06	5.83e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	6.72e-06	5.81e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	6.71e-06	5.8e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	6.69e-06	5.79e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	6.68e-06	5.78e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	6.66e-06	5.76e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.65e-06	5.75e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	6.63e-06	5.74e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	6.63e-06	5.73e-05	CbGpPWpGaD
Epinephrine—SLC22A1—Metabolism—EP300—urinary bladder cancer	6.62e-06	5.73e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	6.61e-06	5.71e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	6.61e-06	5.71e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	6.59e-06	5.7e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	6.58e-06	5.69e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.56e-06	5.67e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	6.54e-06	5.66e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	6.52e-06	5.64e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	6.5e-06	5.62e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	6.48e-06	5.61e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	6.44e-06	5.57e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	6.44e-06	5.57e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.42e-06	5.55e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	6.4e-06	5.54e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	6.4e-06	5.53e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	6.34e-06	5.48e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	6.33e-06	5.47e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	6.28e-06	5.43e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	6.24e-06	5.4e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	6.23e-06	5.39e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.21e-06	5.37e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	6.21e-06	5.37e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	6.18e-06	5.35e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	6.18e-06	5.34e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	6.11e-06	5.28e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	6.09e-06	5.27e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	6.07e-06	5.25e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	6.07e-06	5.25e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	6.06e-06	5.24e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	6.01e-06	5.2e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	6e-06	5.19e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	5.98e-06	5.17e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	5.97e-06	5.16e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	5.96e-06	5.16e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	5.94e-06	5.13e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	5.89e-06	5.09e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	5.88e-06	5.09e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	5.85e-06	5.06e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	5.84e-06	5.05e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	5.84e-06	5.05e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	5.78e-06	5e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	5.77e-06	4.99e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	5.69e-06	4.92e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	5.63e-06	4.87e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	5.62e-06	4.86e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Metabolism—EP300—urinary bladder cancer	5.61e-06	4.85e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.55e-06	4.8e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	5.54e-06	4.79e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	5.53e-06	4.78e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	5.52e-06	4.77e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	5.49e-06	4.74e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	5.47e-06	4.73e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	5.44e-06	4.7e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	5.44e-06	4.7e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	5.39e-06	4.66e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	5.33e-06	4.61e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.32e-06	4.6e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	5.32e-06	4.6e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	5.32e-06	4.6e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	5.31e-06	4.59e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	5.3e-06	4.58e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	5.27e-06	4.56e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	5.23e-06	4.52e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	5.2e-06	4.5e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.16e-06	4.46e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.1e-06	4.41e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.1e-06	4.41e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	5.1e-06	4.41e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	5.05e-06	4.37e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	5.03e-06	4.35e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	5.03e-06	4.35e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	4.98e-06	4.31e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	4.95e-06	4.28e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	4.95e-06	4.28e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	4.93e-06	4.26e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	4.92e-06	4.26e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	4.92e-06	4.26e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	4.92e-06	4.25e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	4.91e-06	4.25e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	4.9e-06	4.24e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.88e-06	4.22e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	4.85e-06	4.19e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.79e-06	4.15e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	4.73e-06	4.09e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	4.69e-06	4.06e-05	CbGpPWpGaD
Epinephrine—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	4.69e-06	4.05e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	4.65e-06	4.02e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	4.58e-06	3.96e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	4.56e-06	3.95e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.55e-06	3.93e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.51e-06	3.9e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	4.47e-06	3.86e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	4.43e-06	3.83e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	4.4e-06	3.81e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	4.37e-06	3.78e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.36e-06	3.77e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	4.3e-06	3.72e-05	CbGpPWpGaD
Epinephrine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	4.27e-06	3.69e-05	CbGpPWpGaD
Epinephrine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	4.23e-06	3.66e-05	CbGpPWpGaD
Epinephrine—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	4.18e-06	3.61e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	4.13e-06	3.58e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	4.09e-06	3.54e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	4.07e-06	3.52e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	4.07e-06	3.52e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	4e-06	3.46e-05	CbGpPWpGaD
Epinephrine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	3.95e-06	3.42e-05	CbGpPWpGaD
Epinephrine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	3.89e-06	3.37e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3.8e-06	3.29e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	3.78e-06	3.27e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.72e-06	3.22e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.65e-06	3.16e-05	CbGpPWpGaD
Epinephrine—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.63e-06	3.14e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	3.61e-06	3.13e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.51e-06	3.04e-05	CbGpPWpGaD
Epinephrine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	3.46e-06	2.99e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	3.36e-06	2.9e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.25e-06	2.81e-05	CbGpPWpGaD
Epinephrine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	3.21e-06	2.78e-05	CbGpPWpGaD
Epinephrine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.1e-06	2.68e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.87e-06	2.49e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.51e-06	2.17e-05	CbGpPWpGaD
Epinephrine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.39e-06	2.07e-05	CbGpPWpGaD
